New FDA guidance: cell therapies and patient identifiers
When the US Food and Drug Administration (FDA) recently made two draft guidance documents for the cell and gene therapies available for comment, the Vineti…
sedApta Group and Vineti partner to develop integrated digital supply chain and manufacturing solution for cell and gene therapies
The sedApta Group, a global software provider specialized in innovative IT solutions for digital Supply Chain and Smart Manufacturing, and Vineti, the provider of the…
Cell and gene therapies: the necessity of a purpose-built platform
Given the wide array of CRMs and other digital systems already serving healthcare and biopharma, that reality might sound like overkill. But after more than…
Gene therapies – simpler doesn’t mean simple
Cell and gene therapies are produced and delivered via the most complex workflows in the history of medicine. Among those workflows, though, there’s a range…
Vineti secures new patent from USPTO for individualized medicine platform
SAN FRANCISCO, March ##, 2022 (GLOBE NEWSWIRE) – Vineti, Inc., the provider of the leading digital platform of record for cell and gene therapies, today…
Cell and gene therapies – new treatments, new value
At the recent Gene Therapy for Rare Disorders conference in Boston, I had the opportunity to discuss thoughts on value with an audience dedicated to…
Vineti’s Personalized Therapy Management® (PTM) solution meets rigorous standards: Service Organization Control (SOC®) 2 Type II compliance audit
Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy…
Vineti achieves SOC2 Type II compliance
Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics, today announced the successful completion of its Service Organization Control (SOC®)…
Vineti introduces new PTM® Integration Suite: purpose-built connectivity and interoperability for cell and gene therapies
Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy…
Why an integrated, digital cell and gene therapy (CGT) ecosystem protects patients and their privacy
Cell and gene therapies (CGTs) are modern, technologically advanced therapies that rely on a complex value chain for manufacturing and patient treatment. Patients are at…
Why CGT 3.0 success depends on interoperability
The cutting edge therapies of CGT 3.0 require modern operations. That means far more than just stand-alone digital systems and select integrations — it means…
How integrated digital systems solve key challenges with cell and gene therapies (CGTs)
One patient. One cell therapy. Ten or more distinct digital systems.
That’s often the number of heterogeneous digital systems across care sites, manufacturers, and…